Replimune Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 122
Employees
  • Stock Symbol
  • REPL
Stock Symbol
  • Share Price
  • $42.68
  • (As of Monday Closing)

Replimune General Information

Description

Replimune Group Inc is a clinical-stage biotechnology company. Its use proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. The company's pipeline products include RP1, RP2, and RP3.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18 Commerce Way
  • Woburn, MA 01801
  • United States
+1 (781) 000-0000

Replimune Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Replimune Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$42.68 $45.20 $8.58 - $47.96 $1.96B 45.9M 567K -$1.66

Replimune Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019 FY 2018 31-Mar-2018
EV 873,754 226,523 344,833
Revenue 0 0 0 0
EBITDA (56,964) (50,173) (30,686) (19,593)
Net Income (60,610) (52,625) (30,834) (19,702)
Total Assets 329,583 234,097 154,326 65,151
Total Debt 43,150 41,789 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Replimune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial

Replimune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial

Replimune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Replimune Group Inc is a clinical-stage biotechnology company. Its use proprietary Immulytic platform to design and deve
Biotechnology
Woburn, MA
122 As of 2020
00000
0000 0000-00-00
00000000 00000

00000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Emeryville, CA
000 As of 0000
00000
000000 - 000 00000

000000 0

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Replimune Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gritstone Oncology Formerly VC-backed Emeryville, CA 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
00000000 Formerly VC-backed Oslo, Norway 00 000.00 000000000 000.00
000000000 00000000 Formerly PE-Backed Oklahoma City, OK 000 0000 000000&0 0000
You’re viewing 5 of 33 competitors. Get the full list »

Replimune Executive Team (13)

Name Title Board Seat Contact Info
Philip Astley-Sparke Chief Executive Officer & Founder
Jean Franchi Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Colin Love Chief Operating Officer, Operations
Pamela Esposito Ph.D Executive
Tess Schmalbach Executive Medical Director
You’re viewing 5 of 13 executive team members. Get the full list »

Replimune Board Members (11)

Name Representing Role Since
Dieter Weinand Self Chairman & Board Member 000 0000
Hyam Levistsky Self Board Member 000 0000
Jason Rhodes Atlas Venture Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
Kapil Dhingra MD Forbion Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Replimune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Replimune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial